

Pictet - Biotech - HR dm ZAR / LU2353392264 / A3CS8J / Pictet AM (EU)

Last 10/02/2024 <sup>1</sup>	Region	Branch	Type of yield	Type
7808.36 ZAR	Worldwide	Sector Biotechnology	paying dividend	Equity Fund



**Risk key figures**

SRI: 1 2 3 4 **5** 6 7

Mountain-View Funds Rating<sup>2</sup>: **EDA<sup>3</sup>**

73

**Yearly Performance**

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	3.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.05%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	1.00%	Performance fee	0.00%
Tranch volume	(10/02/2024) USD 8.09 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(10/02/2024) USD 1,593.51 mill.	<b>Dividends</b>		<b>Investment company</b>	
Launch date	6/22/2021	23.09.2024	41.00 ZAR	Pictet AM (EU) 6B, rue du Fort Niedergruenewald, 2226, Luxembourg Luxembourg www.am.pictet/de/germany	
KEST report funds	Yes	21.08.2024	41.00 ZAR		
Business year start	01.10.	23.07.2024	41.00 ZAR		
Sustainability type	Ethics/ecology	21.06.2024	41.00 ZAR		
Fund manager	Tazio Storni, Lydia Haueter, Marco Minonne, Eugénio Martin-Fougeroux	22.05.2024	41.00 ZAR		

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	-6.51%	+6.44%	+6.97%	+28.70%	-	-	-	+29.93%
Performance p.a.	-	-	-	+28.61%	-	-	-	+18.83%
Sharpe ratio	-3.03	0.45	0.28	1.06	-	-	-	0.72
Volatility	19.95%	22.38%	22.13%	24.00%	0.00%	0.00%	0.00%	21.72%
Worst month	-	-7.73%	-7.73%	-11.37%	-11.37%	0.00%	0.00%	-11.37%
Best month	-	6.86%	18.77%	18.77%	18.77%	0.00%	0.00%	18.77%
Maximum loss	-6.51%	-9.89%	-14.93%	-14.93%	0.00%	0.00%	0.00%	-

**Distribution permission**

Austria, Germany, Switzerland, Luxembourg, Czech Republic

<sup>1</sup> Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

<sup>2</sup> The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

<sup>3</sup> Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit [EDA](#)

**Pictet - Biotech - HR dm ZAR / LU2353392264 / A3CS8J / Pictet AM (EU)**

**Investment strategy**


In actively managing the Compartment, the investment manager uses a combination of market and fundamental company analysis to select securities that it believes offer favourable growth prospects at a reasonable price. The investment manager considers ESG factors a core element of its strategy by seeking to invest mainly in economic activities that contribute to a social objective whilst avoiding activities that adversely affect society or the environment. Voting rights are methodically exercised and there may be engagement with companies to positively influence ESG practices. For further information, please refer to our exclusion framework in the Responsible Investment policy\*, SFDR product category Article 9. The portfolio composition is not constrained relative to the benchmark, so the similarity of the Compartment's performance to that of the benchmark may vary.

**Investment goal**


To increase the value of your investment while seeking to achieve a positive social impact. Reference Index MSCI AC World (USD), an index that does not take into account environmental, social and governance (ESG) factors. Used for risk monitoring, performance objective and performance measurement. Portfolio Assets The Compartment mainly invests in equities of companies operating in the medical biotechnology sector. The Compartment may invest worldwide, including in emerging markets and Mainland China, although most of investments are concentrated in the United States of America and Western Europe.

**Assessment Structure**


**Assets**



**Largest positions**



**Countries**



**Branches**

